CareDx, Inc. $CDNA Shares Sold by Deutsche Bank AG

Deutsche Bank AG lessened its stake in CareDx, Inc. (NASDAQ:CDNA) by 3.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 122,604 shares of the company’s stock after selling 4,088 shares during the quarter. Deutsche Bank AG owned about 0.22% of CareDx worth $2,176,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Sterling Capital Management LLC boosted its holdings in shares of CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock valued at $27,000 after purchasing an additional 1,126 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of CareDx by 20,200.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company’s stock valued at $79,000 after acquiring an additional 4,444 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of CareDx by 553.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company’s stock valued at $84,000 after acquiring an additional 3,322 shares during the period. State of Wyoming purchased a new position in shares of CareDx in the 4th quarter valued at $91,000. Finally, Morse Asset Management Inc purchased a new position in shares of CareDx in the 1st quarter valued at $103,000.

CareDx Stock Performance

NASDAQ CDNA opened at $12.17 on Thursday. CareDx, Inc. has a one year low of $10.96 and a one year high of $33.92. The company has a 50-day simple moving average of $15.82 and a 200-day simple moving average of $17.89. The firm has a market capitalization of $647.81 million, a PE ratio of 11.93 and a beta of 2.22.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.28). CareDx had a net margin of 17.97% and a return on equity of 18.03%. The business had revenue of $90.51 million during the quarter, compared to analyst estimates of $90.72 million. During the same period last year, the firm posted $0.25 earnings per share. The company’s quarterly revenue was down 6.1% on a year-over-year basis. Equities analysts forecast that CareDx, Inc. will post -0.9 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on CDNA shares. HC Wainwright reissued a “neutral” rating and issued a $25.00 target price on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a “hold” rating to a “sell” rating in a research note on Saturday, August 2nd. Wells Fargo & Company cut their target price on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Friday, August 8th. Craig Hallum cut their target price on shares of CareDx from $40.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Finally, Stephens reaffirmed an “overweight” rating and set a $40.00 price target on shares of CareDx in a research note on Monday, May 5th. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, CareDx currently has an average rating of “Moderate Buy” and an average price target of $27.67.

Insider Buying and Selling at CareDx

In other CareDx news, Director Peter Maag sold 10,000 shares of the business’s stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $18.58, for a total transaction of $185,800.00. Following the completion of the transaction, the director directly owned 308,846 shares of the company’s stock, valued at $5,738,358.68. The trade was a 3.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Hannah Valantine sold 10,570 shares of the business’s stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $19.16, for a total transaction of $202,521.20. Following the transaction, the director directly owned 38,994 shares of the company’s stock, valued at $747,125.04. The trade was a 21.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 79,961 shares of company stock valued at $1,490,102 in the last ninety days. Company insiders own 4.40% of the company’s stock.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.